ArticleJournal of virology2026
Immunogenicity of recombinant vesicular stomatitis virus-vectored vaccines expressing the Machupo virus glycoprotein in different genome positions.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Recombinant vesicular stomatitis virus (rVSV) is a powerful vaccine platform that elicits durable cellular and humoral immune responses. rVSV vaccines have successfully been used for various hemorrhagic fever-causing viruses. Here, we create and evaluate rVSV vaccines for Machupo virus (MACV), a highly pathogenic New World (NW) mammarenavirus that causes Bolivian hemorrhagic fever. VSV genome rearrangements impact attenuation of the viral vector and the immune response to the vaccine. Therefore, in this study, we directly compare the effect of altering the MACV glycoprotein complex (GPC) position in the VSV genome on humoral and cellular immune responses to vaccination by evaluating replication, antigen expression, and immunogenicity of rVSVs expressing MACV GPC in the first position of the genome (rVSV-MACV1) and in the traditional glycoprotein gene position (rVSV-MACV5). rVSV-MACV1 expresses higher levels of MACV GPC in infected cells and in virions, but the increased antigen does not translate to a more robust immune response. rVSV-MACV5 elicits higher levels of total IgG and neutralizing antibodies than rVSV-MACV1, but similar levels of MACV-specific T cells. To further investigate vaccine strategies for MACV and other NW arenaviruses such as Junín virus (JUNV), we evaluated the humoral immune response to sequential immunization with rVSVs expressing MACV and JUNV GPCs. The highest levels of MACV and JUNV reactive antibodies were achieved using an rVSV-MACV5 prime followed by rVSV-JUNV boost. The data from our study have implications for rVSV vaccine design and provide a foundation for the development of rVSV-vectored vaccines for MACV and other NW arenaviruses.IMPORTANCEMachupo virus (MACV) is a highly pathogenic New World (NW) mammarenavirus that causes Bolivian hemorrhagic fever (BHF). Because of their high mortality rates, MACV and other NW arenaviruses represent a significant public health threat. However, no approved vaccines for MACV exist. Here, we describe recombinant vesicular stomatitis virus (rVSV) vaccines that express the MACV glycoprotein complex (GPC) in different positions of the VSV genome and characterize the humoral and cellular immune response to each. We also investigate sequential immunization with rVSVs expressing MACV GPC and a related NW arenaviral antigen, Junín virus GPC, in an effort to elicit broadly cross-reactive antibody responses. The conclusions from our study are twofold: data presented here provide further understanding of rVSV vaccine vectors and how genome rearrangements can be leveraged for vaccine development, and the results from our study may inform future vaccine development for MACV and other NW arenaviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.